openPR Logo
Press release

Next generation antibody therapeutics market Size to Reach US$ 22.88 Billion by 2033 - Exclusive Report by DataM Intelligence

09-08-2025 03:21 PM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Next generation antibody therapeutics market - DataM Intelligence

Next generation antibody therapeutics market - DataM Intelligence

Next generation antibody therapeutics market reached US$ 9.09 Billion in 2024 from US$ 8.28 Billion in 2023 and is expected to reach US$ 22.88 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/next-generation-antibody-therapeutics-market?sg

Major M&A / big deals (2025)
✅ Bristol-Myers Squibb - BioNTech: BMS signed a landmark co-development / commercialization agreement with BioNTech for a promising bispecific oncology antibody (BNT327) - deal value up to ~$11 billion (includes upfront + milestones).

✅ BioNTech - CureVac (agreement/offer): BioNTech entered an all-stock acquisition agreement for CureVac valued at about $1.25B (announced mid-2025).

✅ AbbVie acquisition activity (2025): AbbVie moved to strengthen immunology/precision modalities via an acquisition of Capstan Therapeutics (reported ~$2.1B) - expanding in vivo delivery and cell/targeted modalities that complement antibody strategies.

Key product / regulatory milestones & launches (2025)

✅ New ADC approvals / launches in 2025 - multiple antibody-drug conjugates entered the clinic-to-market corridor in 2025; two new ADCs had been reported as newly approved by mid-2025 (regulatory momentum for ADC class). One cited ADC approval in 2025: AbbVie's telisotuzumab vedotin (Emrelis) received accelerated FDA approval for a NSCLC indication.

✅ BioNTech next-gen ADC (trastuzumab pamirtecan) - pivotal success: BioNTech reported pivotal study success for its trastuzumab-pamitrecan ADC in breast cancer (partnered with DualityBio) with positive progression-free survival results - driving regulatory discussions/filing plans. This result materially boosted sentiment and share performance.

Make an customized Enquiry for purchasing this Report @ https://www.datamintelligence.com/customize/next-generation-antibody-therapeutics-market?sg

Next generation antibody therapeutics Market Key Drivers:

➠ Advancements in Antibody Engineering
Novel platforms such as bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-engineered antibodies enhance specificity, efficacy, and safety, creating new therapeutic opportunities in oncology, autoimmune diseases, and infectious disorders.

➠ Rising Burden of Chronic and Rare Diseases
The increasing prevalence of cancer, autoimmune conditions, and rare genetic disorders is driving demand for targeted therapies with better outcomes compared to conventional treatments.

➠ Growing Biologics Pipeline
The expanding pipeline of monoclonal antibodies and next-generation formats in late-stage clinical trials reflects strong innovation and investment from pharmaceutical and biotech firms.

➠ Government and Private Sector Investments
Significant R&D funding, coupled with supportive regulatory pathways for breakthrough biologics, is fostering faster product development and commercialization.

➠ Shift Toward Personalized Medicine
Next-generation antibody therapeutics align with precision medicine approaches, offering customized treatment solutions based on genetic and molecular profiling of patients.

Market Segments:
By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered / Fc-fusion & Half-Life Extension, Antibody Fragments & Scaffolds and Others)
By Therapeutic Area (Oncology, Autoimmune & Inflammatory Diseases, Infectious Diseases, Ophthalmology, Rare Diseases and Others)
By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes and Others)
By Region (North America, Europe, Asia-Pacific, South America and the Middle East & Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Next generation antibody therapeutics Market Geographical Share

The adoption of next-generation antibody therapeutics is accelerating worldwide, but the growth pattern varies across regions:

North America holds the largest share, driven by advanced healthcare infrastructure, strong funding for biopharmaceutical research, and high prevalence of chronic and autoimmune diseases. Regulatory support for innovative biologics and rapid clinical adoption of antibody-drug conjugates and bispecific antibodies further strengthen the region's dominance.

Europe follows closely, supported by rising collaborations between academic research centers and biopharma companies. Countries such as Germany, France, and the UK are focusing on personalized medicine approaches, creating demand for advanced antibody therapeutics.

Asia-Pacific is the fastest-growing region, with significant investments in biotechnology, rising patient populations, and government initiatives to improve biologics manufacturing capabilities. China, Japan, and South Korea are emerging hubs for clinical trials and large-scale production.

Latin America and Middle East & Africa are gradually expanding their market presence. Growth in these regions is fueled by improving access to biologic therapies, increasing healthcare spending, and partnerships with global drug manufacturers to expand treatment availability.

Market Key Players:
Key players are F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Biogen, ADC Therapeutics SA and Genmab A/S.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Next generation antibody therapeutics market Size to Reach US$ 22.88 Billion by 2033 - Exclusive Report by DataM Intelligence here

News-ID: 4174151 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

Curative Therapeutics Market Size to Reach US$ 44.95 Billion by 2033 - Exclusive Report by DataM Intelligence
Curative Therapeutics Market Size to Reach US$ 44.95 Billion by 2033 - Exclusive …
Curative therapeutics market reached US$ 19.94 Billion in 2024 from US$ 18.34 Billion in 2023 and is expected to reach US$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033. Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/curative-therapeutics-market?sg Mergers & acquisitions 2025 ✅ Eli Lilly → Verve Therapeutics - Lilly agreed to acquire Verve (deal ≈ $1.0-1.3B depending on CVRs) to secure VERVE-102
Biologics Outsourcing Market Size to Reach US$ 64.57 billion by 2033 - Exclusive Report by DataM Intelligence
Biologics Outsourcing Market Size to Reach US$ 64.57 billion by 2033 - Exclusive …
The Biologics Outsourcing Market was valued at US$ 20.10 billion in 2023, increased to US$ 22.92 billion in 2024, and is projected to reach US$ 64.57 billion by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033. Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/biologics-outsourcing-market?sg Mergers & Acquisitions ✅ Syngene International (India) acquired its first U.S. biologics facility from Emergent Manufacturing Operations Baltimore for $36.5 million.
Gluten-Free Products Industry of 2025: How United States Leading The Top Players - freedom foods Group Limited, Koninklijke Wessanen N.V., Raisio plc, and Dr Schr Ag/ Spa, General Mills
Gluten-Free Products Industry of 2025: How United States Leading The Top Players …
DataM Intelligence has published a new research report on "Gluten-free Products Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Sample PDF Of This Report (Get
North America Flexible Packaging Market Revenue & Investment Outlook | Major Companies likes - Berry Global Inc, Bemis Company, Inc, Sonoco, Sealed Air Corporation
North America Flexible Packaging Market Revenue & Investment Outlook | Major Com …
The North America Flexible Packaging Market is estimated to reach at a CAGR of 5.3% within the forecast period (2024-2031). The North America Flexible Packaging Market receives exhaustive analysis from DataM Intelligence, delivering stakeholders essential market data, emerging industry patterns, and strategic business intelligence. This in-depth research explores the competitive landscape in detail, evaluating market leaders across multiple dimensions including their innovative product offerings, competitive pricing strategies, financial performance metrics, strategic

All 5 Releases


More Releases for ADC

ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments. Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion Key
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology. New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates. New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313. Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg "2023
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment. On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023 Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends. This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering National Semiconductor Nippon Precision Circuits Inc Micro Analog systems Microchip Technology. TelCom Semiconductor, Inc Vishay Siliconix Texas